Browse > Article
http://dx.doi.org/10.7732/kjpr.2018.31.3.218

Anticancer Activity of the Branch Extracts from Vaccinium oldhamii through Cyclin D1 Proteasomal Degradation in Human Cancer Cells  

Park, Su Bin (Department of Medicinal Plant Resources, Andong National University)
Kim, Ha Na (Department of Medicinal Plant Resources, Andong National University)
Park, Gwang Hun (Forest Medicinal Resources Research Center, National Institute of Forest Science)
Son, Ho-Jun (Forest Medicinal Resources Research Center, National Institute of Forest Science)
Eo, Hyun Ji (Forest Medicinal Resources Research Center, National Institute of Forest Science)
Song, Jeong Ho (Forest Medicinal Resources Research Center, National Institute of Forest Science)
Song, Hun Min (Baekdudaegan National Arboretum)
Park, Ji Ae (Baekdudaegan National Arboretum)
Jeong, Jin Boo (Department of Medicinal Plant Resources, Andong National University)
Publication Information
Korean Journal of Plant Resources / v.31, no.3, 2018 , pp. 218-227 More about this Journal
Abstract
In this study, we investigated the effect of the extracts from Vaccinium oldhamii on cell proliferation and the regulatory mechanisms of cyclin D1 protein level in human cancer cells. The branch extracts from Vaccinium oldhamii (VOB) showed higher inhibitor effect against the cell growth than leave extracts (VOL) and fruit extracts (VOF) in human colorectal cancer, breast cancer, prostate cancer, non-small lung cancer, pancreatic cancer and liver cancer cells. In addition, VOB decreased cyclin D1 level at both protein and mRNA level. MG132 treatment attenuated VOB-mediated cyclin D1 downregulation. A point mutation of threonine-286 to alanine attenuated cyclin D1 degradation by VOB. In addition, the inhibition of nuclear export by leptomycin B (LMB) attenuated cyclin D1 degradation by VOB. But, the treatment of PD98059 (ERK1/2 inhibitor), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), LiCl ($GSK3{\beta}$ inhibitor), LY294002 (PI3K inhibitor) or BAY 11-7082 ($I{\kappa}K$ inhibitor) did not affect VOB-induced cyclin D1 degradation. In conclusion, VOB induced cyclin D1 degradation through redistribution of cyclin D1 from the nucleus to cytoplasm via T286 phosphorylation of cyclin D1, which resulted in the inhibition of cancer cell proliferation.
Keywords
Chemoprevention; Chemotherapy; Functional plant resources; Proteasomal degradation;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Jung, K.W., Y.J. Won, H.J. Kong and E.S. Lee. 2018. Prediction of Cancer Incidence and Mortality in Korea, 2018. Cancer Res. Treat. 50:317-323.   DOI
2 Karjalainen, E., T. Sarjala and H. Raitio. 2010. Promoting human health through forests: overview and major challenges. Environ. Health Prev. Med. 15:1-8.   DOI
3 Kris-Etherton, P.M., K.D. Hecker, A. Bonanome, S.M. Coval, A.E. Binkoski, K.F. Hilpert, A.E. Griel and T.D. Etherton. 2002. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med. 113:71S-88S.   DOI
4 Kristt, D., I. Turner, R. Koren, E. Ramadan and R. Gal. 2000. Overexpression of cyclin D1 mRNA in colorectal carcinomas and relationship to clinicopathological features: an in situ hybridization analysis. Pathol. Oncol. Res. 6:65-70.   DOI
5 Kwak, Y.T., R. Li, C.R. Becerra, D. Tripathy, E.P. Frenkel and U.N. Verma. 2005. IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. J. Biol. Chem. 280:33945-33952.   DOI
6 Lee, J.H., K.T. Lee, J.H. Yang, N.I. Baek and D.K. Kim. 2004. Acetylcholinesterase inhibitors from the twigs of Vaccinium oldhami Miquel. Arch. Pharm. Res. 27:53-56.   DOI
7 Mahadevappa, R and H.F. Kwok. 2017. Phytochemicals - A novel and prominent source of anti-cancer drugs against colorectal cancer. Comb. Chem. High Throughput Screen. 20:376-394.
8 Mhawech, P., V. Greloz, C. Oppikofer, I. Szalay-Quinodoz and F. Herrmann. 2004. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer 100:2367-2375.   DOI
9 Musgrove, E.A., C.E. Caldon, J. Barraclough, A. Stone and R.L. Sutherland. 2011. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11:558-572.   DOI
10 Moreno-Bueno, G., S. Rodriguez-Perales, C. Sanchez-Estevez, R. Marcos, D. Hardisson, J.C. Cigudosa and J. Palacios. 2004. Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. Int. J. Cancer 110: 194-200.   DOI
11 Oh, S.J. and S.C. Koh. 2009. Screening of antioxidative activity and a-amylase inhibitory activity in angiosperm plants native to Jeju Island. Korean J. Plant Res. 22:71-77.
12 Okabe, H., S.H. Lee, J. Phuchareon, D.G. Albertson, F. McCormick and O. Tetsu. 2006. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PloS One 1:e128.   DOI
13 Park, S.B., G.H. Park, H.M. Song, H.J. Son, Y. Um, H.S. Kim, J.B. Jeong. 2017. Anticancer activity of calyx of Diospyros kaki Thunb. through downregulation of cyclin D1 via inducing proteasomal degradation and transcriptional inhibition in human colorectal cancer cells. BMC Complement. Altern. Med. 17:445.   DOI
14 Russell, A., M.A. Thompson, J. Hendley, L. Trute, J. Armes and D. Germain. 1999. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 18:1983-1991.   DOI
15 Tan, P.G., Z. Xing and Z.Q. Li. 2004. Expression of cyclin D1 in brain gliomas and its significance. Chin. J. Cancer. 23:63-65.
16 Seybt, T.P., P. Ramalingam, J. Huang, S.W. Looney and M.D. Reid. 2012. Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland: diagnostic and biologic implications. Appl. Immunohistochem. Mol. Morphol. 20:124-130.   DOI
17 Siegel, R.L., K.D. Miller and A. Jemal. 2018. Cancer statistics, 2018. CA: Cancer J. Clin. 68:7-30.   DOI
18 Stendahl, M., A. Kronblad, L. Ryden, S. Emdin, N.O. Bengtsson and G. Landberg. 2004. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br. J. Cancer. 90: 1942-1948.   DOI
19 Thoms, H.C., M.G. Dunlop and L.A. Stark. 2007. p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res. 67:1660-1669.   DOI
20 Uhari, M., T. Kontiokari, M. Koskela and M. Niemela. 1996. Xylitol chewing gum in prevention of acute otitis media: double blind randomised trial. BMJ 313:1180-1184.   DOI
21 Wall, M.E. and M.C. Wani. 1995. Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 55:753-760.
22 Wu, M.Y., C.X. Zhuang, H.X. Yang and Y.R. Liang. 2004. Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study. World J. Gastroenterol.10:476-480.   DOI
23 Baldin, V., J. Lukas, M.J. Marcote, M. Pagano and G. Draetta. 1993. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:812-821.   DOI
24 Alao, J.P. 2007. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 6:24.
25 Baba, T., D. Hirose, N. Sasaki, N. Watanabe, N. Kobayashi, Y. Kurashige, F. Karimi and T. Ban. 2016. Mycorrhizal Formation and Diversity of Endophytic Fungi in Hair Roots of Vaccinium oldhamii Miq. in Japan. Microbes. Environ. 31:186-189.   DOI
26 Balcerczak, E., G. Pasz-Walczak, P. Kumor, M. Panczyk, R. Kordek, R. Wierzbicki and M. Mirowski. 2005. Cyclin D1 protein and CCND1 gene expression in colorectal cancer. Eur. J. Surg. Oncol. 31:721-726.   DOI
27 Gillett, C., V. Fantl, R. Smith, C. Fisher, J. Bartek, C. Dickson, D. Barnes and G. Peters. 1994. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54:1812-1817.
28 Chao, D.L., C.A. Sanchez, P.C. Galipeau, P.L. Blount, T.G. Paulson, D.S. Cowan, K. Ayub, R.D. Odze, P.S. Rabinovitch and B.J. Reid. 2008. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin. Cancer Res. 14:6988-6995.   DOI
29 Diehl, J.A., M. Cheng, M.F. Roussel and C.J. Sherr. 1998. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12: 3499-3511.   DOI
30 Diehl, J.A., F. Zindy and C.J. Sherr. 1997. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11:957-972.   DOI
31 Hirotoshi, T., K. Hisato, K.T. Ryoko, N. Kazuo, Y. Masao, K. Haruki and Y. Chizyko. 2013. Antioxidant activities and anti-cancer cell proliferation properties of Natsuhaze (Vaccinium oldhamii Miq.), Shashanbo (V. bracteatum Thunb.) and Blueberry cultivars. Plants 2:57-71.   DOI
32 Hunter, T and J. Pines. 1994. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79:573-582.   DOI
33 Joo, H.G. 2003. Altered maturation of dendritic cells by taxol, an anticancer drug. J. Vet. Sci. 4:229-234.